trending Market Intelligence /marketintelligence/en/news-insights/trending/bcwDZ8QJLftzJXfkNpPAfw2 content esgSubNav
In This List

Adamis resubmits new drug application to FDA for anaphylaxis treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Adamis resubmits new drug application to FDA for anaphylaxis treatment

Adamis Pharmaceuticals Corp. resubmitted a new drug application to the U.S. FDA for epinephrine prefilled syringe product candidate for the emergency treatment of anaphylaxis, an extreme and severe allergic reaction.

The resubmission seeks to address issues raised by the agency in its June complete response letter.